# AIMIFY SUBTLEAL





Al-powered Contrast Enhancement for Brain MRI






# AiMIFY is

#### **Innovation**

#### **Because:**

- is the first FDA cleared and CE (MDR) marked Al software of its kind
- recognizes brain tissue up-taking contrast
- · selectively amplifies contrast enhancement up to two¹times\*
- \* the contrast enhancement obtained with a labeled dose of the GBCA.
- 1. Pasumarthi S. et al. 2025 (Preprint)




### Virtual relaxivity

#### **Because:**

- increases small and large contrast-enhancing lesions visibility<sup>1</sup>
- by improving image quality metrics\*
- without changing the **standard of image acquisition**
- \* Contrast-to-noise ratio (CNR), contrast enhancement percentage (CEP), lesion-to-brain ration (LBR). 1. Pasumarthi S. et al. 2025 (Preprint)



# Seamless integration in your workflow



## Virtual dose flexibility

#### **Because:**

- · delivers high-dose-like appearance, on demand
- offers a potentially safer alternative to higher Gd doses
- · doesn't interfere with image acquisition











FDA 510(k) cleared.

Please refer to the AiMIFY User Manual for full safety and use information. AiMIFY is a trademark of Bracco Imaging S.p.A.

 ${\it Manufactured for Bracco Imaging by Subtle Medical Inc., Menlo Park, CA, USA.}$ 

#### www.bracco.com



Bracco Copyright © 2025 | Registered office: Via Egidio Folli 50, 20134 Milan, Italy Share Capital €104.000.000 f. p. | VAT Milan Comp. Reg. n. 00825120157 | Milan REA n. 348182